Bevacizumab-Controlled Delivery from Polymeric Microparticle Systems as Interesting Tools for Pathologic Angiogenesis Diseases

Abstract

This work is a comparative study among three different biocompatible and biodegradable polymers, poly(lactic-co-glycolic acid), poly(ε-caprolactone), and poly(lactic acid), used to produce microparticles for the encapsulation of bevacizumab for drug delivery purposes. All the formulations were produced using the double emulsion water-oil-water evaporation method and characterized in terms of particle mean diameter, particle size distribution, and bevacizumab entrapment efficiency. Bevacizumab cumulative release was taken into consideration to study the dissolution kinetics from the three different polymeric delivery platforms for a period of 50 days at 37 °C in phosphate buffered saline and mathematical models of the drug release kinetic were attempted in order to describe the release phenomena from the different types of the studied microparticles. Finally, cell viability on human endothelial cell line EA.hy926 was studied to define the maximum cytocompatible concentration for each microsystem, registering the mitochondrial functionality through MTS assay.

Controlled release of therapeutic antibody using hydrolytically degradable microgels

“…Pathological angiogenesis is developed in several diseases such as ophthalmic disorders, cancer, and osteoarthritis. 3,20 The use of antiangiogenic antibodies has emerged as potential therapeutics to treat these pathologies. Microgel and nanoparticle carrier systems have been developed for the controlled delivery of bevacizumab and other anti-VEGF drugs.…”

“…Microgel and nanoparticle carrier systems have been developed for the controlled delivery of bevacizumab and other anti-VEGF drugs. 1,3,[6][7][8][18][19][20][21] In this study, we demonstrate the controlled delivery of bevacizumab, modified with a thiol-terminated PEG molecule, using hydrolytically degradable PEG-4MAL microgels. As previously discussed, PEGylation of antibodies is a common strategy to enhance the bioavailability of the target protein.…”

“…Several microcarrier systems have been reported for bevacizumab delivery in recent years. 1,3,7,8,[18][19][20] Most of these microcarriers are synthesized using water-in-oil emulsion methodologies, 1,3,7,8,21 which lack precise control over microcarrier size distribution and drug encapsulation. Additionally, the degradation of these microcarriers cannot be controlled in a timedependent manner.…”

The Genoa Vascular Biobank: A Today Resource for Future Perspectives in Vascular Research

“…In the context of vascular drug delivery, our experience relies on hemocompatibility studies by using blood provided by the GTB from healthy donors to prove the hemocompatibility of nanoliposomes [39] and of antibody-decorated polymeric nanoparticles [40].…”

Development of L-Lysine-Loaded PLGA Microparticles as a Controlled Release System for Angiogenesis Enhancement

“…In this circumstance, tissue engineering and regenerative medicine moved forward the development of biomaterial-based strategies to enhance vasculogenesis by providing pro-angiogenic agents in a controlled manner over time. In particular, several nano- and microparticle-based drug delivery systems (DDSs) were developed for the controlled release of a huge variety of compounds such as growth factors (i.e., vascular endothelial, platelet-derived, and placental growth factors), cells (i.e., human mesenchymal stem cells and Chinese hamster ovary cells), cell-derived materials (i.e., exposomes derived from adipose stem cells), decellularized matrices (i.e., the human placental matrix), antibodies (i.e., bevacizumab), peptides, DNA (i.e., polydeoxyribonucleotide), and RNA [ 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ].…”